Learning Objective for Session 1-A Radio HTRS: Basic Science “Science Friday”
At the close of this session, attendees will be able to:
- Identify new discoveries and “hot topics” in the areas of hemostasis, platelet biology, and thrombosis and vascular biology
- Explain new findings emanating from discovery-based studies
- Evaluate the potential impact of newly described findings on the existing knowledge of underlying biology, biochemistry, and cell biology of hemostasis and thrombosis
Learning Objective for Session 1-B Radio HTRS: Clinical Science “Wait Up, HTRS - Sports Participation When There is a Risk for Bleeding"
At the close of this session, attendees will be able to:
- Identify and feel more comfortable advising patients with VTE on participation in contact sports that put them at risk for bleeding if they are on anticoagulation
- Discuss the concept of a personalized pharmacokinetic/pharmacodynamic DOAC study, “safe” residual anticoagulation blood levels, and return-to-play decision making
- Evaluate an intermittent anticoagulation strategy in non-elite and high-level athletes engaged in contact sports
- Review current recommendations for participation in physical activity in patients with hemophilia
- Explore pharmacokinetic aspects of factor replacement in hemophilia patients participating in contact sports
Learning Objective for Session 1-C Radio HTRS: Translational Science “All Things Considered”
At the close of this session, attendees will be able to:
- Discuss VTE biomarkers that have clinical relevance
- Identify steps required for actionable clinical translation of VTE biomarkers
- Discuss and evaluate the ideal gene therapy delivery system for hemophilia A and B
Learning Objective for Session 2-A HT at the Bedside and Bench: “Sticks and Stones: Hemophilia and Bone Health”
At the close of this session, attendees will be able to:
- Discuss bone health and clinical relevance to people with hemophilia
- Identify screening recommendations for bone health in people with hemophilia
- Discuss treatment recommendations for people with hemophilia and decreased bone
Learning Objective for Session 2-B HT at the Bedside and Bench: “How I Treat/Manage: Bridging Science to Clinical Care”
At the close of this session, attendees will be able to:
- Discuss the risk of thrombosis and its evaluation among transgender individuals
- Evaluate the Use of Direct Oral Anticoagulants in Pediatrics
Learning Objective for Session 2-C HT at the Bedside and Bench: "Omics" Boot Camp
At the close of this session, attendees will be able to:
- Describe current efforts to use “omics” research strategies to advance understanding of hemostasis and thrombosis
- Discuss major findings from recent “omics” studies and their impact on knowledge of genes and proteins involved in hemostasis and thrombosis
- Evaluate the relative advantages and disadvantages of different “omics” approaches
Learning Objective for Session 3 Plenary: “Do We Dare to DOAC?”
At the close of this session, attendees will be able to:
- Evaluate risks and benefits of DOACs vs warfarin in double positive APS patients
- Describe settings in which DOACs are a reasonable alternative to warfarin in APS
- Compare the efficacy of DOACs to warfarin for prevention of arterial thrombosis in APS
Learning Objective for Session 4 Plenary: “VWF Biology”
At the close of this session, attendees will be able to:
- Describe new developments in von Willebrand Disease management
- Discuss VWF as a target in acquired VWF disease
- Evaluate VWF levels and processing in health and disease
Learning Objective for Session 5 State-of-the-Art-Lecture: "VITT, COVID-thrombosis, and Long COVID"
At the close of this session, attendees will be able to:
- Discuss the pathophysiology and mechanisms of vaccine-induced immune thrombotic thrombocytopenia (VITT)
- Explain how VITT is similar to and differs from heparin-induced thrombocytopenia (HIT)
- Discuss potential mechanisms of thrombosis in Long-Covid
Learning Objective for Session 6 Oral Abstract Presentations
At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.
Learning Objective for Session 7-A Hemostasis and Thrombosis in Special Populations: “Pregnancy”
At the close of this session, attendees will be able to:
- Describe at least 2 dosing approaches to LMWH in pregnancy
- Explain the role of TXA in preventing PPH
- Discuss the risks and benefits of transitioning from DOAC to LMWH before vs after positive pregnancy test
Learning Objective for Session 7-B Hemostasis and Thrombosis in Special Populations: “Sickle Cell Disease”
At the close of this session, attendees will be able to:
- Discuss hormone use and its association with thrombosis in Sickle cell disease
- Describe and differentiate processes of venous clot formation in Sickle cell disease
- Discuss prevention of thrombosis in Sickle cell disease
Learning Objective for Session 7-C Hemostasis and Thrombosis in Special Populations: “Pediatrics”
At the close of this session, attendees will be able to:
- Discuss challenges (particularly thrombocytopenia) and different anticoagulants utilized in cancer associated thrombosis
- Explore on bivalirudin advantages and challenges compared to heparin focusing on dosing, monitoring, and reversal strategies
- Review potential benefit versus challenges with concurrent emicizumab and ITI
Learning Objective for Session 8 Oral Abstract Presentations
At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.
Learning Objective for Session 9 Speed Poster Session and In-Person Presentations
At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.
Learning Objective for Session 10-A Bench, Clinic, and Everything In Between: “Connecting Megakaryocyte and Platelet Biology to the Clinic”
At the close of this session, attendees will be able to:
- Describe the process of platelet production from their precursor cells in the bone marrow
- Explain how platelet and megakaryocyte research is guiding clinical diagnosis of bleeding and thrombotic disorders
- Evaluate common platelet disorders based on aberrant platelet and megakaryocyte phenotypes
Learning Objective for Session 10-B Bench, Clinic, and Everything In Between: “Trauma Induced Coagulopathy: Mechanisms and Management”
At the close of this session, attendees will be able to:
- Identify major barriers to effectively treating trauma-induced coagulopathy
- Explain mechanisms of endothelial dysfunction after trauma
- Evaluate multiple blood product different treatment options post-trauma and their pros and cons for patient morbidity and mortality